Related Experiment Videos

Loss of heterozygosity at the human RAP1A/Krev-1 locus is a rare event in colorectal tumors

J Young1, J Searle, R Stitz

  • 1Queensland Cancer Fund Research Unit, Joint Oncology Program, Queensland Institute of Medical Research, Herston, Australia.

Cancer Research
|January 15, 1992
PubMed

Insights

Kirsten-ras-revertant-1 (Krev-1) gene inactivation is not commonly caused by loss of heterozygosity in colorectal cancer. Other inactivation mechanisms may still play a role in tumor development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Kirsten-ras-revertant-1 (Krev-1/Rap1A) is a tumor suppressor gene.
  • Krev-1 induces flat revertants in ras-transformed cell lines.
  • High Krev-1 expression is observed in normal colonic mucosa.

Purpose of the Study:

  • To investigate if Krev-1 locus inactivation is necessary for colonic cell transformation.
  • To analyze loss of heterozygosity at the Krev-1 locus in sporadic colorectal cancer.

Main Methods:

  • Identified a BclI restriction fragment length polymorphism for Krev-1.
  • Analyzed loss of heterozygosity in 52 sporadic colorectal cancer patients.
  • Assessed polymorphism heterozygosity in 50 unrelated individuals.

Main Results:

  • A BclI polymorphism with 40% heterozygosity was identified.
  • Only one out of 18 informative tumors showed allelic loss at the Krev-1 locus.
  • Loss of heterozygosity is not a common inactivation mechanism for Krev-1 in colorectal cancer.

Conclusions:

  • Loss of heterozygosity is infrequent as a mechanism for Krev-1 inactivation in colorectal cancer.
  • The study does not rule out other mechanisms of Krev-1 inactivation.
  • Further research is needed to understand Krev-1's role in colorectal cancer etiology.

Related Concept Videos